PCSK9 monoclonal antibody reduces serum level of lipoprotein(a) :Recent study advances / 中华老年医学杂志

ABSTRACT

Lipoprotein (a)[Lp(a)] is the independent risk tactors tor arteriosclerotic cardiovascular disease(ASCVD).Lp (a) combined with traditional risk factors can increase accurate prediction of the risk for ASCVD.The serum Lp(a)level is correlated with multiple-vessel disease,coronary artery plaque load,vulnerable plaque and in-stent restenosis.Lp(a)is related with coronary artery calcification,calcified aortic stenosis and heart failure.Therefore,Lp(a)level is an independent risk factor for cardiovascular events in ASCVD patients.The proprotein convertase subtilisin/kexin type 9 (PCSK9)monoclonal antibody can decrease the levels of low-density lipoprotein cholesterol and Lp(a),and further reduce the residual risk of major adverse cardiovascular events in ASCAD patients on the basis of statin therapy.